Premium
Evaluation of a bedtime dose of a combination antihistamine/analgesic/decongestant product on antigen challenge the next morning
Author(s) -
Majchel Abraham M.,
Proud David,
KageySobotka Anne,
Witek Theodore J.,
Lichtenstein Lawrence M.,
Naclerio Robert M.
Publication year - 1992
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1288/00005537-199203000-00016
Subject(s) - antihistamine , decongestant , bedtime , medicine , chlorpheniramine maleate , analgesic , morning , pseudoephedrine , anesthesia , pharmacology , ephedrine , chemistry , chromatography
Abstract The effects of CAAD (diphenhydramine hydrochloride, 50 mg; pseudoephedrine hydrochloride, 60 mg; acetaminophen, 1 g in 10% ethanol) were evaluated in a double‐blind, three‐way, placebo‐controlled, cross‐over study on 18 volunteers with allergic rhinitis. The number of sneezes following nasal challenge with antigen was significantly reduced after a bedtime dose of CAAD ( P <.005) and a single dose of diphenhydramine ( P <.001) given 2 hours before the challenge. The levels of N‐alpha‐tosyl‐L‐arginine methyl ester (TAME) activity decreased after diphenhydramine treatment, while histamine levels following challenge were not different. The drowsiness reported after CAAD was equal to placebo, but significantly less than diphenhydramine ( P <.002 for both). The active treatments reduced the actions of histamine without suppressing its release from mast cells. The effect of CAAD persists 10 hours after administration without inducing drowsiness.